Current surgical treatment of squamous cell carcinoma of the head and neck

Oral Oncology

Volumn 43, Issue 3, 2007, Pages 213-223

  Yao, Mike ^a   Epstein, Joel B ^a   Modi, Bijal J ^a   Pytynia, Kristen B ^a   Mundt, Arno J ^a   Feldman, Lawrence E ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Chemoradiotherapy; Head and neck cancer; IMRT; Organ preservation; Radiation therapy; Targeted therapy

Indexed keywords

AMIFOSTINE; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; METHOTREXATE; PLATINUM; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RADIOSENSITIZING AGENT; TIRAPAZAMINE;

ADD ON THERAPY; CANCER ADJUVANT THERAPY; CANCER SURGERY; DRUG RESPONSE; DYSARTHRIA; DYSPHAGIA; HEAD AND NECK CARCINOMA; HUMAN; HYPOXIA; LARYNGECTOMY; LARYNX; LARYNX PROSTHESIS; LARYNX SURGERY; LASER SURGERY; METASTASIS; MICROSURGERY; MORBIDITY; MOUTH HYGIENE; MUCOSA INFLAMMATION; NEPHROTOXICITY; PATIENT CARE; PEDICLED SKIN FLAP; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RECURRENT DISEASE; REVIEW; SKIN FLAP; SOFT TISSUE; SPEECH REHABILITATION; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; SWALLOWING; THERAPY EFFECT; TREATMENT OUTCOME;

CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; LARYNGEAL NEOPLASMS; NECK; PHARYNGEAL NEOPLASMS; RADIOTHERAPY, ADJUVANT; RECONSTRUCTIVE SURGICAL PROCEDURES; SALVAGE THERAPY; SPEECH; SURGICAL FLAPS; TREATMENT OUTCOME;

EID: 33846881778     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2006.04.013     Document Type: Review

References (108)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 2 (2006) 106-130
2. Devita V., Hellman S., and Rosenberg S. Cancer: principle and practice of oncology. Cancer of the head and neck (2001), Lippincott, Williams and Wilkins, Philadelphia 789-915
3. Vokes E.E., Weichselbaum R.R., Lippman S.M., and Hong W.K. Head and neck cancer. N Engl J Med 328 3 (1993) 184-194
4. Al-Sarraf M. Chemotherapeutic management of head and neck cancer. Cancer Metastasis Rev 6 3 (1987) 181-198
5. Cohen E.E., Lingen M.W., and Vokes E.E. The expanding role of systemic therapy in head and neck cancer. J Clin Oncol 22 9 (2004) 1743-1752
6. Saunders M.I., and Rojas A.M. Management of cancer of the head and neck-a cocktail with your PORT?. N Engl J Med 350 19 (2004) 1997-1999
7. Kowalski L.P., and Carvalho A.L. Natural history of untreated head and neck cancer. Eur J Cancer 36 8 (2000) 1032-1037
8. Forastiere A., Koch W., Trotti A., and Sidransky D. Head and neck cancer. N Engl J Med 345 26 (2001) 1890-1900
9. Lamont E.B., and Vokes E.E. Chemotherapy in the management of squamous-cell carcinoma of the head and neck. Lancet Oncol 2 5 (2001) 261-269
10. Rodgers Jr. L.W., Stringer S.P., Mendenhall W.M., Parsons J.T., Cassisi N.J., and Million R.R. Management of squamous cell carcinoma of the floor of mouth. Head Neck 15 1 (1993) 16-19
11. Petrovich Z., Parker R.G., Luxton G., Kuisk H., and Jepson J. Carcinoma of the lip and selected sites of head and neck skin. A clinical study of 896 patients. Radiother Oncol 8 1 (1987) 11-17
12. Cerezo L., Liu F.F., Tsang R., and Payne D. Squamous cell carcinoma of the lip: analysis of the Princess Margaret Hospital experience. Radiother Oncol 28 2 (1993) 142-147
13. Marsiglia H., Haie-Meder C., Sasso G., Mamelle G., and Gerbaulet A. Brachytherapy for T1-T2 floor-of-the-mouth cancers: the Gustave-Roussy Institute experience. Int J Radiat Oncol Biol Phys 52 5 (2002) 1257-1263
14. Mazeron J.J., Simon J.M., Le Pechoux C., et al. Effect of dose rate on local control and complications in definitive irradiation of T1-2 squamous cell carcinomas of mobile tongue and floor of mouth with interstitial iridium-192. Radiother Oncol 21 1 (1991) 39-47
15. Fein D.A., Mendenhall W.M., Parsons J.T., et al. Carcinoma of the oral tongue: a comparison of results and complications of treatment with radiotherapy and/or surgery. Head Neck 16 4 (1994) 358-365
16. Mazeron J.J., Crook J.M., Benck V., et al. Iridium 192 implantation of T1 and T2 carcinomas of the mobile tongue. Int J Radiat Oncol Biol Phys 19 6 (1990) 1369-1376
17. Wang C.C., Kelly J., August M., and Donoff B. Early carcinoma of the oral cavity: a conservative approach with radiation therapy. J Oral Maxillofac Surg 53 6 (1995) 687-690
18. Mendenhall W.M., Amdur R.J., Morris C.G., and Hinerman R.W. T1-T2N0 squamous cell carcinoma of the glottic larynx treated with radiation therapy. J Clin Oncol 19 20 (2001) 4029-4036
19. Le Q.T., Fu K.K., Kroll S., et al. Influence of fraction size, total dose, and overall time on local control of T1-T2 glottic carcinoma. Int J Radiat Oncol Biol Phys 39 1 (1997) 115-126
20. Spector J.G., Sessions D.G., Chao K.S., et al. Stage I (T1 N0 M0) squamous cell carcinoma of the laryngeal glottis: therapeutic results and voice preservation. Head Neck 21 8 (1999) 707-717
21. Hinerman R.W., Mendenhall W.M., Amdur R.J., Stringer S.P., Villaret D.B., and Robbins K.T. Carcinoma of the supraglottic larynx: treatment results with radiotherapy alone or with planned neck dissection. Head Neck 24 5 (2002) 456-467
22. Amdur R.J., Mendenhall W.M., Parsons J.T., Isaacs Jr. J.H., Million R.R., and Cassisi N.J. Carcinoma of the soft palate treated with irradiation: analysis of results and complications. Radiother Oncol 9 3 (1987) 185-194
23. Remmler D., Medina J.E., Byers R.M., Meoz R., and Pfalzgraf K. Treatment of choice for squamous carcinoma of the tonsillar fossa. Head Neck Surg 7 3 (1985) 206-211
24. Mendenhall W.M., Amdur R.J., Stringer S.P., Villaret D.B., and Cassisi N.J. Radiation therapy for squamous cell carcinoma of the tonsillar region: a preferred alternative to surgery?. J Clin Oncol 18 11 (2000) 2219-2225
25. Housset M., Baillet F., Dessard-Diana B., Martin D., and Miglianico L. A retrospective study of three treatment techniques for T1-T2 base of tongue lesions: surgery plus postoperative radiation, external radiation plus interstitial implantation and external radiation alone. Int J Radiat Oncol Biol Phys 13 4 (1987) 511-516
26. Mendenhall W.M., Parsons J.T., Stringer S.P., Cassisi N.J., and Million R.R. Radiotherapy alone or combined with neck dissection for T1-T2 carcinoma of the pyriform sinus: an alternative to conservation surgery. Int J Radiat Oncol Biol Phys 27 5 (1993) 1017-1027
27. Harrison L.B., Zelefsky M.J., Armstrong J.G., Carper E., Gaynor J.J., and Sessions R.B. Performance status after treatment for squamous cell cancer of the base of tongue-a comparison of primary radiation therapy versus primary surgery. Int J Radiat Oncol Biol Phys 30 4 (1994) 953-957
28. Amdur R.J., Mendenhall W.M., Stringer S.P., Villaret D.B., and Cassisi N.J. Organ preservation with radiotherapy for T1-T2 carcinoma of the pyriform sinus. Head Neck 23 5 (2001) 353-362
29. Harrison L.B., Solomon B., Miller S., Fass D.E., Armstrong J., and Sessions R.B. Prospective computer-assisted voice analysis for patients with early stage glottic cancer: a preliminary report of the functional result of laryngeal irradiation. Int J Radiat Oncol Biol Phys 19 1 (1990) 123-127
30. Steiner W., Fierek O., Ambrosch P., Hommerich C.P., and Kron M. Transoral laser microsurgery for squamous cell carcinoma of the base of the tongue. Arch Otolaryngol Head Neck Surg 129 1 (2003) 36-43
31. Steiner W., Ambrosch P., Hess C.F., and Kron M. Organ preservation by transoral laser microsurgery in piriform sinus carcinoma. Otolaryngol Head Neck Surg 124 1 (2001) 58-67
32. Ambrosch P., Kron M., and Steiner W. Carbon dioxide laser microsurgery for early supraglottic carcinoma. Ann Otol Rhinol Laryngol 107 8 (1998) 680-688
33. Pradier O., Christiansen H., Schmidberger H., et al. Adjuvant radiotherapy after transoral laser microsurgery for advanced squamous carcinoma of the head and neck. Int J Radiat Oncol Biol Phys (2005)
34. Hicks Jr. W.L., Loree T.R., Garcia R.I., et al. Squamous cell carcinoma of the floor of mouth: a 20-year review. Head Neck 19 5 (1997) 400-405
35. Franceschi D., Gupta R., Spiro R.H., and Shah J.P. Improved survival in the treatment of squamous carcinoma of the oral tongue. Am J Surg 166 4 (1993) 360-365
36. Sessions D.G., Spector G.J., Lenox J., Haughey B., Chao C., and Marks J. Analysis of treatment results for oral tongue cancer. Laryngoscope 112 4 (2002) 616-625
37. Malone J.P., Stephens J.A., Grecula J.C., Rhoades C.A., Ghaheri B.A., and Schuller D.E. Disease control, survival, and functional outcome after multimodal treatment for advanced-stage tongue base cancer. Head Neck 26 7 (2004) 561-572
38. Posner M.R., Glisson B., Frenette G., et al. Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol 19 4 (2001) 1096-1104
39. Vokes E.E., Stenson K., Rosen F.R., et al. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol 21 2 (2003) 320-326
40. Cooper J.S., Pajak T.F., Forastiere A., et al. Precisely defining high-risk operable head and neck tumors based on RTOG #85-03 and #88-24: targets for postoperative radiochemotherapy?. Head Neck 20 7 (1998) 588-594
41. Bernier J., Domenge C., Ozsahin M., et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350 19 (2004) 1945-1952
42. Cooper J.S., Pajak T.F., Forastiere A.A., et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350 19 (2004) 1937-1944
43. Browman G.P., and Cronin L. Standard chemotherapy in squamous cell head and neck cancer: what we have learned from randomized trials. Semin Oncol 21 3 (1994) 311-319
44. Wendt T.G., Grabenbauer G.G., Rodel C.M., et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 16 4 (1998) 1318-1324
45. Calais G., Alfonsi M., Bardet E., et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 91 24 (1999) 2081-2086
46. Brizel D.M., Albers M.E., Fisher S.R., et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 338 25 (1998) 1798-1804
47. Adelstein D.J., Li Y., Adams G.L., et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21 1 (2003) 92-98
48. Argiris A., Stenson K.M., Brockstein B.E., et al. Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer. Head Neck 26 5 (2004) 447-455
49. McHam S.A., Adelstein D.J., Rybicki L.A., et al. Who merits a neck dissection after definitive chemoradiotherapy for N2-N3 squamous cell head and neck cancer?. Head Neck 25 10 (2003) 791-798
50. Stenson K.M., Haraf D.J., Pelzer H., et al. The role of cervical lymphadenectomy after aggressive concomitant chemoradiotherapy: the feasibility of selective neck dissection. Arch Otolaryngol Head Neck Surg 126 8 (2000) 950-956
51. Lavertu P., Adelstein D.J., Saxton J.P., et al. Management of the neck in a randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer. Head Neck 19 7 (1997) 559-566
52. Clayman G.L., Johnson II C.J., Morrison W., Ginsberg L., and Lippman S.M. The role of neck dissection after chemoradiotherapy for oropharyngeal cancer with advanced nodal disease. Arch Otolaryngol Head Neck Surg 127 2 (2001) 135-139
53. Ariyan S. The pectoralis major myocutaneous flap. A versatile flap for reconstruction in the head and neck. Plast Reconstr Surg 63 1 (1979) 73-81
54. Vartanian J.G., Carvalho A.L., Carvalho S.M., Mizobe L., Magrin J., and Kowalski L.P. Pectoralis major and other myofascial/myocutaneous flaps in head and neck cancer reconstruction: Experience with 437 cases at a single institution. Head Neck 26 12 (2004) 1018-1023
55. Spriano G., Pellini R., and Roselli R. Pectoralis major myocutaneous flap for hypopharyngeal reconstruction. Plast Reconstr Surg 110 6 (2002) 1408-1413 discussion 1414-6
56. Engroff S.L. Fibula flap reconstruction of the condyle in disarticulation resections of the mandible: a case report and review of the technique. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 100 6 (2005) 661-665
57. Takushima A., Harii K., Asato H., Momosawa A., Okazaki M., and Nakatsuka T. Choice of osseous and osteocutaneous flaps for mandibular reconstruction. Int J Clin Oncol 10 4 (2005) 234-242
58. Seikaly H., Maharaj M., Rieger J., and Harris J. Functional outcomes after primary mandibular resection and reconstruction with the fibular free flap. J Otolaryngol 34 1 (2005) 25-28
59. Teoh K.H., Huryn J.M., Patel S., et al. Implant prosthodontic rehabilitation of fibula free-flap reconstructed mandibles: a Memorial Sloan-Kettering Cancer Center review of prognostic factors and implant outcomes. Int J Oral Maxillofac Implants 20 5 (2005) 738-746
60. Izdebski K., Reed C.G., Ross J.C., and Hilsinger Jr. R.L. Problems with tracheoesophageal fistula voice restoration in totally laryngectomized patients. A review of 95 cases. Arch Otolaryngol Head Neck Surg 120 8 (1994) 840-845
61. Kearney A. Nontracheoesphageal speech rehabilitation. Otolaryngol Clin North Am 37 3 (2004) 613-625
62. Singer M.I., and Blom E.D. An endoscopic technique for restoration of voice after laryngectomy. Ann Otol Rhinol Laryngol 89 6 Pt 1 (1980) 529-533
63. Tardy-Mitzell S., Andrews M.L., and Bowman S.A. Acceptability and intelligibility of tracheoesophageal speech. Arch Otolaryngol 111 4 (1985) 213-215
64. Lewin J.S., Bishop-Leone J.K., Forman A.D., and Diaz Jr. E.M. Further experience with Botox injection for tracheoesophageal speech failure. Head Neck 23 6 (2001) 456-460
65. Chao S.S., Graham S.M., and Hoffman H.T. Management of pharyngoesophageal spasm with Botox. Otolaryngol Clin North Am 37 3 (2004) 559-566
66. Hamaker R.C., and Blom E.D. Botulinum neurotoxin for pharyngeal constrictor muscle spasm in tracheoesophageal voice restoration. Laryngoscope 113 9 (2003) 1479-1482
67. Hoffman H.T., Fischer H., VanDenmark D., et al. Botulinum neurotoxin injection after total laryngectomy. Head Neck 19 2 (1997) 92-97
68. Zormeier M.M., Meleca R.J., Simpson M.L., et al. Botulinum toxin injection to improve tracheoesophageal speech after total laryngectomy. Otolaryngol Head Neck Surg 120 3 (1999) 314-319
69. Van Weissenbruch R., and Albers F.W. Vocal rehabilitation after total laryngectomy using the Provox voice prosthesis. Clin Otolaryngol Allied Sci 18 5 (1993) 359-364
70. Saurajen A.S., Chee N.W., Siow J.K., Lim F., Mok P.K., and Earnest A. Tracheoesophageal puncture outcomes and predictors of success in laryngectomised patients. Ann Acad Med Singapore 29 4 (2000) 452-456
71. Ameye D., Honraet K., Loose D., Vermeersch H., Nelis H., and Remon J.P. Effect of a buccal bioadhesive nystatin tablet on the lifetime of a Provox silicone tracheoesophageal voice prosthesis. Acta Otolaryngol 125 3 (2005) 304-306
72. Jacobs C., Goffinet D.R., Goffinet L., Kohler M., and Fee W.E. Chemotherapy as a substitute for surgery in the treatment advanced resectable head and neck cancer. A report from the Northern California Oncology Group. Cancer 60 6 (1987) 1178-1183
73. Lefebvre J.L., Chevalier D., Luboinski B., Kirkpatrick A., Collette L., and Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 88 13 (1996) 890-899
74. Forastiere A.A., Goepfert H., Maor M., et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349 22 (2003) 2091-2098
75. The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 324 24 (1991) 1685-1690
76. Paccagnella A., Orlando A., Marchiori C., et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 86 4 (1994) 265-272
77. Domenge C., Hill C., Lefebvre J.L., et al. Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tete et du Cou (GETTEC). Br J Cancer 83 12 (2000) 1594-1598
78. Rooney M., Kish J., Jacobs J., et al. Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin. Cancer 55 5 (1985) 1123-1128
79. Thyss A., Schneider M., Santini J., et al. Induction chemotherapy with cis-platinum and 5-fluorouracil for squamous cell carcinoma of the head and neck. Br J Cancer 54 5 (1986) 755-760
80. Pignon J.P., Bourhis J., Domenge C., and Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 355 9208 (2000) 949-955
81. Schrijvers D. Phase I-II trial of docetaxel, cisplatin and fluorouracil in patients with locally advanced inoperable squamous cell carcinoma of the head and neck. In: Proceedings from the American society clinical oncology annual meeting. 1999; 18: p. 394q.
82. Zorat P.L., Paccagnella A., Cavaniglia G., et al. Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up. J Natl Cancer Inst 96 22 (2004) 1714-1717
83. Laccourreye O., Brasnu D., Biacabe B., Hans S., Seckin S., and Weinstein G. Neo-adjuvant chemotherapy and supracricoid partial laryngectomy with cricohyoidopexy for advanced endolaryngeal carcinoma classified as T3-T4: 5-year oncologic results. Head Neck 20 7 (1998) 595-599
84. Catimel G. Head and neck cancer: guidelines for chemotherapy. Drugs 51 1 (1996) 73-88
85. Morton R.P., Rugman F., Dorman E.B., et al. Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial. Cancer Chemother Pharmacol 15 3 (1985) 283-289
86. Forastiere A.A., Metch B., Schuller D.E., et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a southwest oncology group study. J Clin Oncol 10 8 (1992) 1245-1251
87. Chmura S.J., Milano M.T., and Haraf D.J. Reirradiation of recurrent head and neck cancers with curative intent. Semin Oncol 31 6 (2004) 816-821
88. De Crevoisier R., Bourhis J., Domenge C., et al. Full-dose reirradiation for unresectable head and neck carcinoma: experience at the Gustave-Roussy Institute in a series of 169 patients. J Clin Oncol 16 11 (1998) 3556-3562
89. De Crevoisier R., Domenge C., Wibault P., et al. Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma. Cancer 91 11 (2001) 2071-2076
90. Milano MT, Vokes EE, Salama JK, et al. Twice daily re-irradiation of recurrent and second primary head and neck cancer with gemcitabine, paclitaxel adn fluorouracil chemotherapy. In: Proceedings from the American society clinical oncology annual meeting, 2004; 91: p. 2071-76.
91. Machtay M., Rosenthal D.I., Chalian A.A., et al. Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer. Int J Radiat Oncol Biol Phys 59 1 (2004) 72-77
92. Lee D.J., Cosmatos D., Marcial V.A., et al. Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus etanidazole with radiotherapy alone for locally advanced head and neck carcinomas. Int J Radiat Oncol Biol Phys 32 3 (1995) 567-576
93. van den Bogaert W., van der Schueren E., Horiot J.C., et al. Early results of the EORTC randomized clinical trial on multiple fractions per day (MFD) and misonidazole in advanced head and neck cancer. Int J Radiat Oncol Biol Phys 12 4 (1986) 587-591
94. Overgaard J., Hansen H.S., Overgaard M., et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish head and neck cancer study (DAHANCA) protocol 5-85. Radiother Oncol 46 2 (1998) 135-146
95. Fu K.K., Pajak T.F., Trotti A., et al. A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 48 1 (2000) 7-16
96. Haraf D.J., Rosen F.R., Stenson K., et al. Induction chemotherapy followed by concomitant TFHX chemoradiotherapy with reduced dose radiation in advanced head and neck cancer. Clin Cancer Res 9 16 Pt 1 (2003) 5936-5943
97. Jeremic B., Shibamoto Y., Milicic B., et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 18 7 (2000) 1458-1464
98. Harrison L.B., Raben A., Pfister D.G., et al. A prospective phase II trial of concomitant chemotherapy and radiotherapy with delayed accelerated fractionation in unresectable tumors of the head and neck. Head Neck 20 6 (1998) 497-503
99. Trotti A., Bellm L.A., Epstein J.B., et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol 66 3 (2003) 253-262
100. Leibel S.A., Fuks Z., Zelefsky M.J., et al. Intensity-modulated radiotherapy. Cancer J 8 2 (2002) 164-176
101. Xing L., Wu Q., Yong Y., et al. Physics of IMRT and inverse treatment planning. In: Mundt A., and Roeske J. (Eds). Intensity modulated radiation therapy: a clinical perspective (2005), BC Decker, Hamilton, Canada
102. Chao K.S., Majhail N., Huang C.J., et al. Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: a comparison with conventional techniques. Radiother Oncol 61 3 (2001) 275-280
103. Lee N., Xia P., Quivey J.M., et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys 53 1 (2002) 12-22
104. Chao K.S., Ozyigit G., Tran B.N., Cengiz M., Dempsey J.F., and Low D.A. Patterns of failure in patients receiving definitive and postoperative IMRT for head-and-neck cancer. Int J Radiat Oncol Biol Phys 55 2 (2003) 312-321
105. Wu Q., Manning M., Schmidt-Ullrich R., and Mohan R. The potential for sparing of parotids and escalation of biologically effective dose with intensity-modulated radiation treatments of head and neck cancers: a treatment design study. Int J Radiat Oncol Biol Phys 46 1 (2000) 195-205
106. Lin A., Kim H.M., Terrell J.E., Dawson L.A., Ship J.A., and Eisbruch A. Quality of life after parotid-sparing IMRT for head-and-neck cancer: a prospective longitudinal study. Int J Radiat Oncol Biol Phys 57 1 (2003) 61-70
107. Rubenstein E.B., Peterson D.E., Schubert M., et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100 9 Suppl (2004) 2026-2046
108. Epstein J.B., and Schubert M.M. Oropharyngeal mucositis in cancer therapy. Review of pathogenesis, diagnosis, and management. Oncology (Williston Park) 17 12 (2003) 1767-1779 discussion 1779-82, 1791-2